Track topics on Twitter Track topics that are important to you
Teva Pharmaceutical Industries' twice-daily tablet Vantrela ER, or hydrocodone bitartrate, has been endorsed for approval by -More-
JERUSALEM--(BUSINESS WIRE)--Jun. 7, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety ...
FDA's Anesthetic and Analgesic Drug Products committee and Drug Safety and Risk Management advisory committee voted 14-3 to recommend approval of Vantrela ER hydrocodone bitartrate (CEP-33237) from Te...
The switch of hydrocodone-containing combination drugs from Schedule III to the more restrictive Schedule II in October 2014 significantly reduced the number of prescriptions filled for these drugs, a...
Collegium Pharmaceutical has unveiled positive topline results from a clinical study evaluating Hydrocodone DETERx as a second product candidate using its proprietary DETERx drug delivery technology p...
FDA's Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management advisory committees will meet in June to discuss pain candidates CEP-33237 from Teva Pharmaceutical Industries Ltd. (NY...
Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
Biphasic immediate-release (IR)/extended-release (ER) hydrocodone bitartrate (HB)/acetaminophen (APAP) 7.5/325-mg tablets are formulated with gastroretentive ER drug delivery technology that has been ...
To assess the single-dose and steady-state pharmacokinetics of a single-entity hydrocodone extended-release (ER) formulation in patients enrolled in two separate phase 2 clinical studies.
The purpose of this study was to evaluate the pharmacokinetics (PK) and 24-hour analgesic effectiveness of once-daily, single-entity, extended-release hydrocodone (HYD) with abuse-deterrent properties...
Evaluate levels of pain relief achieved in patients with chronic pain treated with hydrocodone-extended release (HC-ER) up to 48 weeks and show that these levels were associated with secondary functio...
Immediate-release (IR) hydrocodone is the most widely prescribed opioid in the United States; however, little is known about the utilization patterns and duration of opioid use among patients prescrib...